PDF(Pubmed)
Abstract：
OBJECTIVE: Mesenchymal stem cells (MSCs) present a valuable treatment option for knee osteoarthritis with promising results. The purpose of the present study was to systematically review the clinical and functional outcomes following mesenchymal stem cell application focusing on early to moderate knee osteoarthritis.
METHODS: A systematic search was done using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in Pubmed, Scopus, Web of Science, and Cochrane Library databases. All Studies published between 2017 and March 2023 on patients treated with single mesenchymal stem cell injection for Kellgren-Lawrence grade I-III knee osteoarthritis reported on clinical and functional outcomes were included.
RESULTS: Twelve articles comprising 539 patients and 576 knees treated with a single intraarticular injection of MSCs for knee osteoarthritis were included in the current systematic review. In eligible studies, the reported outcomes were improved concerning patient-reported outcomes measures, knee function, pain relief, and quality of patient\'s life.
CONCLUSIONS: Based on high-level evidence studies, single intraarticular injection of MSCs is a safe, reliable, and effective treatment option for Kellgren-Lawrence grade I-III knee osteoarthritis. However, the lack of homogeneity in the included studies and the variance in MSCs sources and preparations should be noted.
METHODS: III.
METHODS: A systematic search was done using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in Pubmed, Scopus, Web of Science, and Cochrane Library databases. All Studies published between 2017 and March 2023 on patients treated with single mesenchymal stem cell injection for Kellgren-Lawrence grade I-III knee osteoarthritis reported on clinical and functional outcomes were included.
RESULTS: Twelve articles comprising 539 patients and 576 knees treated with a single intraarticular injection of MSCs for knee osteoarthritis were included in the current systematic review. In eligible studies, the reported outcomes were improved concerning patient-reported outcomes measures, knee function, pain relief, and quality of patient\'s life.
CONCLUSIONS: Based on high-level evidence studies, single intraarticular injection of MSCs is a safe, reliable, and effective treatment option for Kellgren-Lawrence grade I-III knee osteoarthritis. However, the lack of homogeneity in the included studies and the variance in MSCs sources and preparations should be noted.
METHODS: III.
摘要：
目的：间充质干细胞（MSCs）为膝骨关节炎提供了一种有价值的治疗选择，并取得了有希望的结果。本研究的目的是系统评价间充质干细胞应用于早期至中度膝骨关节炎的临床和功能结果。
方法：使用Pubmed，Scopus,WebofScience,和Cochrane图书馆数据库。纳入了2017年至2023年3月期间发表的关于Kellgren-LawrenceI-III级膝骨关节炎患者单次间充质干细胞注射治疗的临床和功能结果的所有研究。
结果：目前的系统评价包括12篇文章，包括539例患者和576例膝关节内注射MSCs治疗膝骨关节炎。在符合条件的研究中，报告的结果在患者报告的结果指标方面有所改善，膝关节功能,疼痛缓解,和病人的生活质量。
结论：基于高水平的证据研究，单关节内注射MSCs是一种安全的,可靠,Kellgren-LawrenceI-III级膝骨关节炎的有效治疗选择。然而,应注意纳入研究缺乏同质性,MSCs来源和制备存在差异.
方法：III.
方法：使用Pubmed，Scopus,WebofScience,和Cochrane图书馆数据库。纳入了2017年至2023年3月期间发表的关于Kellgren-LawrenceI-III级膝骨关节炎患者单次间充质干细胞注射治疗的临床和功能结果的所有研究。
结果：目前的系统评价包括12篇文章，包括539例患者和576例膝关节内注射MSCs治疗膝骨关节炎。在符合条件的研究中，报告的结果在患者报告的结果指标方面有所改善，膝关节功能,疼痛缓解,和病人的生活质量。
结论：基于高水平的证据研究，单关节内注射MSCs是一种安全的,可靠,Kellgren-LawrenceI-III级膝骨关节炎的有效治疗选择。然而,应注意纳入研究缺乏同质性,MSCs来源和制备存在差异.
方法：III.
